Breast cancer (BC) is the most frequent cancer diagnosed in women worldwide. This
heterogeneous disease can be classified into four molecular subtypes (luminal A, luminal B …

Estrogen receptors (ERs) regulate multiple complex physiological processes in humans.
Abnormal ER signaling may result in various disorders, including reproductive system …

Breast cancer is the most commonly diagnosed cancer worldwide and is one of the leading
causes of cancer death. The incidence, pathological features, and clinical outcomes in …

Breast cancers with positive expression of Estrogen Receptor (ER+) are treated with anti-
hormone/endocrine therapy which targets the activity of the receptor, the half-life of the …

The estrogen receptor is a vital receptor for therapeutic targets in estrogen receptor-positive
breast cancer. The main strategy for the treatment of estrogen receptor-positive breast …

Introduction The selective estrogen receptor degrader (SERD) and full receptor antagonist
provides an important therapeutic option for hormone receptor (HR)-positive breast cancer …

Physiologic activation of estrogen receptor α (ERα) is mediated by estradiol (E2) binding in
the ligand-binding pocket of the receptor, repositioning helix 12 (H12) to facilitate binding of …

Resistance to cancer therapies has been a commonly observed phenomenon in clinical
practice, which is one of the major causes of treatment failure and poor patient survival. The …

The hedgehog (Hh) pathway plays a key role in embryonic development and stem cell
programs. Deregulation of the Hh pathway is a key driver of basal cell carcinoma, and …

Endometrial carcinomas (ECs) classified by The Cancer Genome Atlas (TCGA) as copy
number-low (also referred to as “no specific molecular profile”[NSMP]) have a prognosis …